Selective depletion of macrophages in atherosclerotic plaques: myth, hype, or reality?
Martinet
Wim
W
De Meyer
Guido R Y
GR
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D050197:Atherosclerosis / Q000473:pathology / Q000503:physiopathology* / Q000517:prevention & control; D039481:CD11b Antigen / Q000235:genetics; D004167:Diphtheria Toxin / Q000494:pharmacology; D004195:Disease Models, Animal; D018450:Disease Progression; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D011956:Receptors, Cell Surface / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism
D039481:CD11b Antigen; D004167:Diphtheria Toxin; C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D011956:Receptors, Cell Surface; D011993:Recombinant Fusion Proteins